Investors Urged to Act: Class Action Updates for Three Stocks

Class Action Alert for Biohaven Ltd.

In a recent update, The Law Offices of Frank R. Cruz has issued a reminder for Biohaven Ltd. (BHVN) shareholders regarding a class action currently in motion. Investors holding shares between March 24, 2023, and May 14, 2025, may be eligible to file a lead plaintiff motion ahead of the deadline on September 12, 2025.

Allegations Against Biohaven

The class action complaint alleges that Biohaven made multiple materially false and misleading statements regarding its business operations and potential. Specifically, it is claimed that the company exaggerated the efficacy of its treatment candidate, troriluzole, for SCA and did not adequately disclose significant concerns regarding another drug, BHV-7000, intended for bipolar disorder treatment. These misleading statements are said to have had a considerable impact on the company’s financial health once revealed.

Attention for Neogen Corporation Investors

Moreover, Neogen Corporation (NEOG) shareholders are also being urged to take note of a class action lawsuit related to inaccuracies in the company’s disclosures. If you held shares from January 5, 2023, to June 3, 2025, make sure to take action by the deadline of September 16, 2025.

Concerns Raised in the Neogen Case

This class action claims that Neogen failed to disclose critical operational challenges faced during its integration with 3M, which had adversely affected sales and financial expectations. Investors are encouraged to reach out if they've incurred significant losses related to this stock.

Class Action Insights for RxSight, Inc.

Additionally, RxSight, Inc. (RXST) is facing allegations in a class action lawsuit regarding securities fraud. The relevant class period extends from November 7, 2024, to July 8, 2025, with a call for potential lead plaintiffs to act by September 22, 2025.

Misleading Statements in RxSight's Case

Investors have raised concerns about the company’s misrepresentation of operational capabilities and projections for adoption of its products. Claims suggest that RxSight overstated product demand, leading to unrealized financial goals, which consequently impacted stock value.

Contacting Legal Representation

Investors who believe they may have grounds for a claim are encouraged to reach out for legal counsel through The Law Offices of Frank R. Cruz. Interested parties can contact them at 310-914-5007 or via email to fcruz@frankcruzlaw.com to discuss their legal rights and potential participation in these class actions.

Why Class Actions Matter

Class actions serve as a powerful tool for protecting investors' rights, allowing individuals to come together against larger entities that have engaged in malpractices. By joining together, shareholders can pursue justice collectively, often leading to settlements that could protect their investments.

Frequently Asked Questions

What should I do if I am a shareholder of the affected companies?

If you have suffered a loss as a shareholder of Biohaven, Neogen, or RxSight, it is advisable to contact The Law Offices of Frank R. Cruz for further guidance.

How can I participate in the class actions?

You can participate by contacting the law office and providing the necessary information concerning your investments in the specified time frames.

What is the deadline to act on these class actions?

The deadlines vary for each company: September 12, 2025, for Biohaven, September 16, 2025, for Neogen, and September 22, 2025, for RxSight.

Will I need to pay any fees to join?

Typically, legal firms cover their fees through settlements or court awards, meaning you should not need to pay upfront fees to participate.

Who can I contact for more information?

You can reach out to The Law Offices of Frank R. Cruz for more information and to discuss your case specifically.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.